Fairvalue-Calculator Fairvalue-Calculator
EN DE

Medexus Pharmaceuticals Inc (MEDXF) Fair Value & Analysis

Healthcare · US · Market cap $94.5M

Price$2.85
Fair Value$4.39
Upside+53.9%
Quality95/100
Evidence: High Range $2.95 – $5.83

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Medexus Pharmaceuticals Inc (MEDXF) currently trades at $2.85, while our model-based Fair Value estimate is $4.39 — implying the stock looks roughly 53.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxac…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Medexus Pharmaceuticals Inc (MEDXF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.39 versus a price of $2.85 — about +54% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MEDXF?
Our 21-model fair value for Medexus Pharmaceuticals Inc is $4.39 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.85.
What is the quality score of MEDXF?
Medexus Pharmaceuticals Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.